secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001628280-25-037923
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Pharma reports Q2 revenue up 10% YoY; YTD revenue +23%
-----------------------------------------------------------------

- Q2 net revenue $10.8M (+10% YoY); YTD net revenue $22.6M (+23%).
- Q2 net loss $741k; YTD net income $516k; adjusted YTD EPS $0.18.
- Ifetroban Phase II DMD trial showed 5.4% improvement in cardiac function; FDA submission completed.
- Vibativ 4-vial starter pak now available via Vizient, covering >65% of U.S. acute care providers.
- Cash and equivalents $16M; total assets $68M; shareholders' equity $28M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828025037923/0001628280-25-037923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828025037923/cpix-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-037923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer